Foamix Pharmaceuticals To Present Latest Data on FMX101

Foamix Pharmaceuticals (NASDAQ:FOMX) announced the presentation of new data related to its two latest posters on candidate FMX101.

As quoted in the press release:

Foamix Pharmaceuticals a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced it will present two late-breaking posters relating to its topical product candidate FMX101, a 4 [percent] minocycline foam being developed for the treatment of moderate-to-severe acne, at the 77 Annual Meeting of the Society for Investigative Dermatology to be held May 8-11, 2019, in Chicago, Illinois. Foamix previously announced that the US Food & Drug Administration (FDA) has accepted the filing of a New Drug Application for FMX101 for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients nine years of age and older and the FDA has set an action date of October 20, 2019 under the Prescription Drug User Fee Act (PDUFA).

Click here to read the full press release.